Eli Lilly and Company will present 16 research abstracts at the Alzheimer's Association International Conference (AAIC). The conference runs from July 12-15 in London. Presentations will feature new clinical insights on its Alzheimer's treatment, Kisunla (donanemab-azbt). These insights come from the TRAILBLAZER-ALZ clinical trials. Data includes new long-term extension findings. It also covers safety related to modified drug titration.
The company will also showcase significant advancements in diagnostic research. A key presentation will reveal data on P-tau217 blood biomarker tests. These tests demonstrated performance comparable to amyloid PET scans. They identify Alzheimer's disease pathology in cognitively unimpaired individuals. This research highlights a potential future for a scalable and accessible blood test. Such a test could enable early disease detection.